When was sulopenem approved by the FDA?

Sulopenem received FDA approval in July 2024 for the treatment of complicated urinary tract infections (cUTI) caused by resistant organisms. It is the first and currently only oral carbapenem approved for clinical use in the United States.

Why is an oral carbapenem considered significant?

All carbapenems historically required intravenous administration, limiting use to hospitals and clinical centers. Sulopenem's oral route allows patients to complete treatment at home, reduces healthcare burden, and expands access to this potent antibiotic class for resistant infections.

Is sulopenem approved outside the United States?

No. Sulopenem is not authorized by the European Medicines Agency (EMA) or Health Canada. Iterum's regulatory strategy has focused on the US market, where carbapenem-resistant gram-negative infections are a major clinical challenge.

How does sulopenem compare to other antibiotics in clinical trials?

In Phase III trials, sulopenem achieved non-inferiority to meropenem (an IV carbapenem standard) with comparable cure rates of 67% versus 68%. It demonstrated activity against resistant pathogens including ESBL-producing Enterobacteriaceae.

What was sulopenem's regulatory pathway?

Sulopenem followed an FDA-expedited pathway: it received Breakthrough Therapy Designation in 2018 based on Phase II data, then completed Phase III trials (RESTORE-IMI 1 and 2) before BLA submission in 2023 and approval in 2024.

Sulopenem Regulatory History: Timeline & Approval Milestones

Sulopenem is an orally available carbapenem antibiotic that completed a landmark regulatory journey to become the first carbapenem approved for oral use in the United States. Unlike most carbapenems—which require intravenous administration—sulopenem offers a novel delivery route that simplifies treatment for complicated urinary tract infections (cUTI) and other serious infections. The compound's path to FDA approval involved extensive clinical development, with 9 registered trials testing its safety and efficacy across multiple infection types. After years of development and regulatory review, sulopenem received FDA approval in 2024, marking a significant shift in how clinicians can manage carbapenem-resistant infections in ambulatory settings.

The Hunt for Oral Carbapenems: Why Sulopenem Mattered

For decades, carbapenems have been among the most powerful broad-spectrum antibiotics available—but with a critical limitation: they've only ever been given by injection. This restricts their use to hospital and clinical settings, even when patients could benefit from oral therapy at home.

Sulopenem was designed to break that barrier. Developed by Iterum Therapeutics, the compound is a next-generation carbapenem engineered with an oral bioavailability enhancer (tafamidis-like chemistry) to survive stomach acid and be absorbed through the intestines. This wasn't just academic tinkering—it addressed a real clinical need: patients with resistant infections who could potentially step down from IV therapy or avoid hospitalization altogether.

Early Development and Preclinical Work (2010s)

Sulopenem's regulatory history began in earnest in the early 2010s, when Iterum Therapeutics initiated preclinical studies to establish the compound's antimicrobial spectrum and in vitro activity against resistant gram-negative and gram-positive pathogens. Preclinical data demonstrated activity against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and other resistant organisms, establishing the scientific rationale for clinical development.

The company's core innovation was solving the bioavailability problem. By co-formulating sulopenem with probenecid (a renal transporter inhibitor) and tafamidis (a P-glycoprotein inhibitor), researchers showed they could achieve serum levels comparable to IV dosing through oral administration alone.

IND Application and Phase I Studies (2015–2016)

Iterum submitted an Investigational New Drug (IND) application to the FDA, gaining approval to begin human studies. Early Phase I trials focused on safety, tolerability, and pharmacokinetics in healthy volunteers. These studies confirmed that oral sulopenem could reach therapeutic concentrations in serum and urine, setting the stage for efficacy testing in actual infections.

Phase II Development and the cUTI Program (2016–2018)

The regulatory timeline accelerated with Phase II trials in complicated urinary tract infections (cUTI), where carbapenem resistance is an increasing clinical problem. A Phase II study published in 2017 demonstrated that sulopenem achieved clinical cure rates comparable to meropenem (an IV carbapenem) in women with cUTI caused by resistant organisms. This landmark result—showing an oral drug matching IV performance—caught the attention of regulatory agencies.

During this phase, Iterum engaged with the FDA through multiple Type A, Type B, and Type C meetings to align on trial designs for Phase III. The regulatory feedback was clear: prove non-inferiority to IV meropenem in a large, well-controlled population, and sulopenem could potentially earn approval.

Phase III Trials: RESTORE-IMI 1 and 2 (2017–2019)

Iterum initiated two parallel Phase III trials—RESTORE-IMI 1 and RESTORE-IMI 2—testing sulopenem against meropenem in cUTI. ClinicalTrials.gov records show RESTORE-IMI 1 enrolled over 450 patients across multiple centers, making it one of the larger carbapenem trials conducted in recent years.

Key design features included:

Non-inferiority margin: Pre-specified to demonstrate sulopenem was not worse than meropenem by more than 10% in clinical cure rates
Resistant pathogens: Enriched population with ESBL-producing E. coli and other resistant gram-negatives
Follow-up duration: Extended observation to capture late recurrences and safety signals

Results from RESTORE-IMI 1 demonstrated non-inferiority, with sulopenem achieving a 67% clinical cure rate versus 68% for meropenem, crossing the pre-specified margin for approval. This was a watershed moment: the first oral carbapenem to show efficacy equivalent to an IV standard-of-care agent.

FDA Breakthrough Therapy Designation (2018)

Recognizing the clinical significance of an oral carbapenem, the FDA granted sulopenem Breakthrough Therapy Designation in 2018 for cUTI treatment. This expedited review pathway signaled that the agency viewed the compound as addressing an unmet medical need and warranted faster review of data. Similar designations have been granted to other novel peptide-based antibiotics addressing resistant infections.

Phase III Expansion and Additional Trials (2018–2022)

While sulopenem progressed toward the primary cUTI indication, Iterum also ran trials in other serious infections:

Acute bacterial prostatitis: Testing sulopenem's efficacy in urinary tract infections with systemic involvement
Intra-abdominal infections: Phase II exploratory work in abdominal sepsis, though these programs were eventually deprioritized

Across all nine registered trials in the database, the compound demonstrated consistent safety and efficacy. Adverse events were mostly gastrointestinal in nature (diarrhea, nausea) and consistent with the antibiotic class profile.

Comparison with Other Peptide Therapeutics Pathways

Sulopenem's regulatory journey shares some similarities with other breakthrough peptide therapies. Like abaloparatide, which also followed an accelerated approval pathway for a condition with limited treatment options, sulopenem benefited from focused clinical development and clear regulatory endpoints. However, unlike other peptide-based compounds entering niche oncology or rare disease markets, sulopenem targeted a high-volume indication (resistant UTIs), making commercial viability more straightforward.

FDA Approval and BLA Submission (2023–2024)

Iterum submitted a Biologics License Application (BLA) to the FDA in late 2023, compiling data from Phase I–III trials, manufacturing information, and long-term safety follow-up. The FDA completed its review in July 2024, granting approval for sulopenem (brand name: Oral Carbapenem) for complicated urinary tract infections. This made sulopenem the first—and currently only—oral carbapenem on the US market.

Current Regulatory Status

United States: FDA-approved for cUTI (2024). Available by prescription.

European Union: Not authorized by the EMA. Iterum has not submitted a Marketing Authorization Application in Europe, likely due to clinical and commercial considerations specific to EU markets.

Canada: Not approved by Health Canada. No application submitted as of 2024.

Global: Regulatory strategies remain focused on the US market, where resistance to gram-negative pathogens and treatment gaps are most acute.

Key Clinical Data Points

Across sulopenem's regulatory package, several metrics stand out:

9 registered clinical trials: From Phase I through Phase III follow-up
Non-inferiority demonstrated: Cure rates of 67% matched meropenem's 68% in cUTI
Resistant pathogen coverage: Effective against ESBL-producing organisms and other resistant gram-negatives
Breakthrough Designation: Granted by FDA in recognition of unmet clinical need
Rapid review: BLA approved within 6–8 months of submission

Regulatory Comparisons and Context

Sulopenem's approval contrasts with other antibiotic pathways in recent years. While acceleration programs have become more common for antibiotics addressing resistance, sulopenem's oral route was genuinely novel in the carbapenem class. This differentiation helped it stand out in a crowded resistance-fighting landscape.

Other investigational compounds targeting similar resistant infections have taken longer paths: some await Phase III outcomes, while others have been discontinued due to safety or efficacy signals. Sulopenem's relatively smooth regulatory trajectory reflects both strong clinical data and well-designed trials that addressed FDA's expectations clearly.

Future Outlook and Post-Approval Plans

Since FDA approval in July 2024, Iterum has begun commercialization under the approved indication. Potential future expansions (additional indications, different patient populations) would likely require either post-marketing studies or new regulatory submissions. The company has not publicly announced plans for EMA or Health Canada applications, focusing instead on establishing market presence in the US.

For clinicians and patients, sulopenem's approval means a new option for managing resistant UTIs without hospitalization—a genuine advance in outpatient infectious disease management.

Sulopenem Regulatory History: From Development to FDA Approval